Recent advances in breast cancer biology

Current Opinion in Oncology

Volumn 10, Issue 6, 1998, Pages 486-491

  Eisen, Andrea ^a   Weber, Barbara L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; ESTROGEN RECEPTOR; PROTEIN BCL 2; RALOXIFENE; TAMOXIFEN; TELOMERASE;

APOPTOSIS; BREAST CANCER; CANCER GENETICS; CANCER SUSCEPTIBILITY; HUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0031755454     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199811000-00002     Document Type: Review

References (45)

1. Mosselman S, Polman J, Dijkema R: ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996, 392:49-53.
2. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustaffson JA: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138:863-870.
3. Paech K, Webb P, Kuiper GG, Nilsson S, Gustaffson JA, Kushner PJ, Scanlan TS: Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277:1508-1510. Examines the transactivation potential ERα and ERα bound to estradiol or antiestrogens, and shows that they have opposite effects at the AP1 site, which represents one possible mechanism of tissue specificity.
4. Dowsett M, Daffada A, Chan CM, Johnston SR: Oestrogen receptor mutants and variants in breast cancer. Eur J Cancer 1997, 33:1177-1183. This article is an excellent review of the subject.
5. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA: An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997, 57:1244-1249.
6. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lupu R: Expression of estrogen receptor beta messenger RNA variant in breast cancer. Cancer Res 1998, 58:210-214.
7. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, et al.: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389:753-758. This article describes the crystal structure of ERα ligand binding domain bound to estradiol and raloxifene. Altered conformation causes differences in transactivation potential, possibly accounting for tissue-specific effects.
8. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al.: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277:965-968. The identification of an ER co-activator that is frequently overexpressed in primary breast tumors is presented.
9. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997, 3:614-620.
10. Papadimitriou CS, Costopoulos JS, Christoforidou BP, Kotsianti AJ, Karkavelas GS, Hytiroglou PM, et al.: Expression of Bcl-2 protein in human primary breast carcinomas and its correlation with multifocality, histopathological types and prognosis. Eur J Cancer 1997, 33:1275-1280.
11. Duenas-Gonzalez A, Abad-Hernandez MM, Cruz-Hernandez JJ, Gonzalez-Sarmiento R: Analysis of bcl-2 in sporadic breast carcinoma. Cancer 1997, 80:2100-2108.
12. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, et al.: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 1998, 48:107-116.
13. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, et al.: bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 1997, 15:1916-1922. In this trial of tamoxifen in women with metastatic breast cancer, bcl-2 expression was associated with favorable prognosis.
14. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC: bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 1998, 82:1296-1302.
15. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33:787-791.
16. Zakian VA: Life and cancer without telomerase. Cell 1997, 91:1-3.
17. Greider CW: Telomerase activity, cell proliferation, and cancer. Proc Natl Acad Sci U S A 1998, 95:90-92.
18. Yashima K, Milchgrub S, Gollahon LS, Maitra A, Saboorian MH, Shay JW, Gadzar AF: Telomerase enzyme activity and RNA expression during the multistage pathogenesis of breast carcinoma. Clin Cancer Res 1998, 4:229-234.
19. Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, et al.: Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998, 19:182-186. This article discusses in situ detection of the catalytic component of telomerase showing limited expression in normal breast tissue and progressively elevated levels with increasing tumorigenicity.
20. Clark GM, Osborne CK, Levitt D, Wu F, Kim NW: Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst 1997, 89:1874-1881.
21. Hanssen AMN, Fryns JP: Cowden Syndrome. J Med Genet 1995, 32:117-119.
22. Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H, et al.: Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997, 6:1383-1387.
23. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al.: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362. This paper and the paper below by Li et al. (Science 1997, 275:1943-1947) describe the identification and characterization of the novel tumor suppressor gene PTEN.
24. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al.: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 13:356-362. This paper and the paper above by Steck et al. (Nat Genet 1997, 15:356-362) describe the identification and characterization of the novel tumor suppressor gene PTEN.
25. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al.: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997, 16:64-67.
26. Tsou HC, Teng DH, Ping XL, Brancolini V, Davis T, Hu R, et al.: The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1 -negative cases. Am J Hum Genet 1997, 61:1036-1043. This paper, along with those of Lynch et al. (Am J Hum Genet 1997, 61:1254-1260) and Chen et al. (Hum Genet 1998, 102:124-125), shows that PTEN mutations are not found in BRCA1- and BRC42-negative breast cancer families.
27. Lynch ED, Ostermeyer EA, Lee MK, Arena JF, Ji H, Dann J, et al.: Inherited mutations in PTEN that are associated with breast cancer, Cowden disease, and juvenile polyposis. Am J Hum Genet 1997, 61:1254-1260. This paper, along with those of Tsou et al. (Am J Hum Genet 1997, 61:1036-1043) and Chen et al. (Hum Genet 1998, 102:124-125), shows that PTEN mutations are not found in BRCA1- and SRCA2-negative breast cancer families.
28. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, et al.: Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum MoI Genet 1998, 7:507-515.
29. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, et al.: P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A 1997, 94:9052-9057.
30. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998, 62:676-689.
31. Chen J, Lindblom P, Lindblom A: A study of the PTEN/MMAC1 gene in 136 breast cancer families. Hum Genet 1998, 102:124-125. This paper, along with those of Tsou et al. (Am J Hum Genet 1997, 61:1036-1043) and Lynch et al. (Am J Hum Genet 1997, 61:1254-1260), shows that PTEN mutations are not found in BRCA1- and BRCA2-negative breast cancer families.
32. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 1997, 57:3657-3659.
33. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, et al.: MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997, 57:5221-5225.
34. Monteiro AN, August A, Hanafusa H: Common BRCA1 variants and transcriptional activation. Am J Hum Genet 1997, 61:761-762.
35. Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, et al.: BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 1997, 94:5605-5610.
36. Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T: Transcriptional activation functions in BRCA2. Nature 1997, 386:772-773.
37. Zhang H, Tombline G, Weber BL: BRCA1, BRCA2, and DNA damage response: collision or collusion? Cell 1998, 92:433-436. Comprehensive review of the role of BRCA1 and BRCA2 in DNA repair.
38. Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM, et al.: Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997, 90:425-435.
39. Husain A, He G, Venkatraman ES, Spriggs DR: BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998, 58:1120-1123.
40. Tr/Tr mouse, which expresses a truncated BRCA2 protein but is still viable, and the resulting phenotype. These animals, and cells derived from them, exhibit features consistent with defective DNA repair capability.
41. Tr/Tr mouse, which expresses a truncated BRCA2 protein but is still viable, and the resulting phenotype. These animals, and cells derived from them, exhibit features consistent with defective DNA repair capability.
42. Breast Cancer Linkage Consortium: Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997, 349:1505-1510. Descriptive study of the pathological features of BRCA1- and BRCA2-associated breast cancer.
43. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD, et al.: Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997, 80:435-441.
44. Johannsson OT, Ranstam J, Borg A, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998, 16:397-404.
45. Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, et al.: BRCA-associated breast cancer in young women. J Clin Oncol 1998, 16:1642-1649.